Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
Roche subsidiary, Genentech, has announced that the US FDA has accepted its supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback